Anteotech Ltd · ASX:ADO

Anteotech — Anteo Diagnostics — Shareholder Meeting (November 2014)

15 slides from Anteotech's shareholder meeting presentation, Nov 10, 2014

  1. Slide 1: Annual General Meeting

    For personal use only Anteo Diagnostics (ASX:ADO) Annual General Meeting 10th November 2014 Welcome The Surface Science Company

  2. Slide 2: Meeting Format

    MEETING FORMAT For personal use only  Introductions  Formal Resolutions  CEO Report  Other Business  Meeting Close Anteo Diagnostics 2

  3. Slide 3: Introductions

    Introductions For personal use only Anteo Diagnostics Limited – Present  Mark Bouris– Non Executive Chairman  Geoff Cumming – CEO  Richard Martin – Executive Director  Sandra Andersen – Non Executive Director  John Hurrell – Non Executive Director Grant Thornton  Matthew Bell – Partner Anteo D

  4. Slide 4: Formal Resolutions

    Formal Resolutions For personal use only Resolution 1: Adoption of Directors’ Remuneration Report Resolution 2: Re- Election of Director (Mr Richard Martin) Resolution 3: Approval of 10% Placement Capacity Resolution 4: Issue of Securities under Executive/Employee Share Plan Resolution 5: Issue of 5

  5. Slide 5: Resolutions – Proxy Count

    RESOLUTIONS – PROXY COUNT For personal use only Description For Against Open Excluded Abstain Totals Adoption of Directors’ Resolution 1 215,294,159 3,717,929 20,000 17,500,000 2,432,978 238,965,066 Remuneration Report Re- Election of Director (Mr Resolution 2 222,925,455 8,059,713 5,995,120 0 1,984

  6. Slide 6: CEO Update

    For personal use only Anteo Diagnostics (ASX:ADO) Annual General Meeting CEO UPDATE The Surface Science Company

  7. Slide 7: 2014 Review

    2014 Review For personal use only • Commercialisation • Technical Development • Internal Skill Set - Personnel • Corporate Activities Anteo Diagnostics 7

  8. Slide 8: Commercialisation

    Commercialisation For personal use only Headline Projects • BBI • Achieved Phase 3 goals • Require better sensitivity • POC 1 • Successful delivery • Expanded scope of study AMG Products • Maturity recognition with customers • Broad interest – tier 1 companies • Delivering new product per quarter An

  9. Slide 9: Commercialisation

    Commercialisation For personal use only Global Presence • Permanent BD capability in 3 time zones • Tina - Europe • Josh - Americas • Rachel – Asia Pacific Paid Research & Collaboration Expanding demands • Diagnostics • Particles • Plates • Plastics and other surfaces • Separations – magnetic partic

  10. Slide 10: Technical Development: New Mix&Go Formulations

    Technical Development For personal use only New Mix&Go Formulations 2012 • Solidify short-term opportunities • Open up full spectrum of uses R&d • Reconfirm concepts upon which Mix&Go is founded Moved from Research to Production Capability • Base Mix&Go components 2014 • End products r&D • Developed

  11. Slide 11: Technical Development: Signal Amplification

    Technical Development For personal use only Signal Amplification • Here & now extending life and utility of lateral flow devices • Generally applicable to assays Application Diversity Plastics Particles Plates Glass 1st gen 1st gen & Mix&Go 2nd gen Ceramics Metals Technical Trifecta: expanded techno

  12. Slide 12: Internal Skill Set (Personnel)

    Internal Skill Set (Personnel) For personal use only New People with the Expertise and Experience to Expand • Manufacture desired Mix&Go • From base components • For specific purposes • Production capability • IVD & POC depth to R&D team especially lateral flow • Techno-commercial skill at tier 1 IV

  13. Slide 13: Corporate Perspective

    Corporate Perspective For personal use only Operational Subsidiary Change of Name Bio-Layer is now Anteo Technologies • To better reflect our brand’s product, patents & potential • Avoids market perception of ‘just diagnostics’ Build Capability and Asset Base • Depth and breadth of products • Core c

  14. Slide 14: Corporate Perspective

    Corporate Perspective For personal use only Strategic outlook: control destiny • Placement • Financial security • Opportunity to build asset base and capability • Own AMG product range Minimise Timeframes to Business Goals • Engaged advisor • Searching alternatives (incl M&A) Commercial Value from P

  15. Slide 15: Thank you very much for your attendance today

    For personal use only Thank you very much for your attendance today. Anteo Diagnostics 15

Anteo Diagnostics — Shareholder Meeting (November 2014) on 6ix